Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 17/20 | 0.70 |
| ▸ | JAK1 | P23458 | 3/20 | 0.70 |
| ▸ | JAK3 | P52333 | 3/20 | 0.70 |
| ▸ | BRDT | Q58F21 | 3/20 | 0.70 |
| ▸ | JAK2 | O60674 | 3/20 | 0.70 |
| ▸ | BRD2 | P25440 | 2/20 | 0.70 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.70 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.66 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.66 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | FLT3 | P36888 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24255886 | 0.93 | BRD4 (0.77) | BRD4JAK1JAK3BRDTJAK2 | |
| SCHEMBL24256003 | 0.92 | EGFR (0.69) | BRD4JAK1JAK3BRDTJAK2 | |
| SCHEMBL24255885 | 0.91 | BRD4 (0.80) | BRD4JAK1JAK3BRDTJAK2 | |
| SCHEMBL24255824 | 0.86 | BRD4 (0.68) | BRD4JAK1JAK3BRDTJAK2 | |
| SCHEMBL24255900 | 0.85 | BRD4 (0.70) | BRD4JAK1JAK3BRDTJAK2 | |
| SCHEMBL26983507 | 0.84 | BRD4 (0.70) | BRD4JAK1JAK3BRDTJAK2 | |
| SCHEMBL24255308 | 0.84 | EGFR (0.70) | BRD4JAK1JAK3BRDTJAK2 | |
| SCHEMBL24255898 | 0.82 | EGFR (0.80) | BRD4EGFR | |
| SCHEMBL18757703 | 0.82 | BRD4 (1.00) | BRD4JAK1JAK3BRDTJAK2 | |
| SCHEMBL17526165 | 0.82 | BRD4 (1.00) | BRD4JAK1JAK3BRDTJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240010634-A1 | PYRIMIDINYL SULFONAMIDES AS INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | NATIONAL INSTITUTES OF HEALTH | 2024-01-11 | — | — | US | disclosed |
| WO-2022036313-A1 | PYRIMIDINYL SULFONAMIDES AS INHIBITORS OF ACK1/TNK1 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240010634-A1 | PYRIMIDINYL SULFONAMIDES AS INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | TNK1, TNNI3K, TNKS2 | BRD4 1316/4885JAK1 575/4885JAK3 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.